Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GV-108
- Development stage
- Phase 1
- Lead developer
- GV20 Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GV-108 is a first-in-class monoclonal antibody targeting Immunoglobulin Superfamily Member 11 (IGSF11), an immune checkpoint protein. Developed by Gv-20 Therapeutics using their proprietary AI-driven STELLAR platform, GV-108 is designed to block the interaction between IGSF11 and its receptors, such as VSIG3, which are often upregulated in the tumor microenvironment to suppress T-cell activity. By inhibiting this checkpoint, GV-108 aims to restore and enhance the immune system's ability to identify and destroy cancer cells. It is currently being investigated in Phase 1 clinical trials for the treatment of advanced or refractory solid tumors, representing a novel approach in the field of cancer immunotherapy.
- Other names
- anti-IGSF11 antibodyanti-IGSF-11 antibodyanti-IGSF 11 antibody
02
Targets
CTA (Cancer-testis antigens)
Beyond the preview
Go deeper on GV-108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GV-108.